Roche Invests US$1.8bn In Infusion-Free Administration Technology

Multinational dug company Roche is investing approximately CHF1.90bn (US$1.82bn) in manufacturing a novel device that will allow patients to self-administer biological cancer medicines. The device will deliver an innovative formula of Herceptin (trastuzumab), a product developed via Roche's collaboration with biopharmaceutical company Halozyme Therapeutics which is currently undergoing phase III clinical

To read the full article, please choose one of the following options: